Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
SciGene Corp.’s Hyb-Ice thermal profiling system performs everyday temperature profiles. The system consists of a programmable heating/cooling base and removable block that heat and cool samples from 4° to 99°C. It accommodates a variety of quick-change blocks to fit nearly any tube or plate.
Quality Laboratory Solutions has added to its LinChek product line of calibration verification/linearity material a chemistry linearity test set. The new test set is a liquid product packaged as six distinct levels with three ampules of 1 mL for each level. Twenty-five different analytes, including the most-requested tests, are included. An 18-month supply of product is available with each test set by providing three separate sets of linearity material.
Hamilton Robotics announced that the CytoScan automated target preparation solution from Affymetrix is built on Hamilton’s customizable Microlab Nimbus 96 workstation. The Nimbus 96 instrument automates target preparation for the CytoScan cytogenetics solution, which offers broad coverage for detecting human chromosomal aberrations.
Streck’s CVA, an assayed linearity control kit used to determine the patient reportable range of three- and five-part hematology instruments, is now assayed for Beckman Coulter’s UniCel DxH 800. CVA establishes an instrument’s reportable range and verifies linearity, testing the instrument’s extreme upper and lower limits, ensuring that patient results are valid.
Nanosphere has obtained the CE-IVD Mark for its gram-negative blood culture test (BC-GN) on the automated sample-to-result Verigene system. The test expands Nanosphere’s infectious disease test capabilities to include rapid detection of bacteria that can cause deadly bloodstream infections.
Oncomatrix’s DMTXinvaScan is an immunohistochemistry-based kit designed to diagnose and predict the invasiveness of pancreas, breast, lung, colon, and head and neck tumors. The main component of DMTXinva-Scan is a monoclonal antibody that detects collagen XI-α1. Oncomatrix developed and clinically validated this antibody.
Biosearch Technologies has acquired exclusive worldwide rights to continuing Stellaris RNA FISH-based inventions from the University of Medicine and Dentistry of New Jersey. In addition to single-molecule detection of mRNA, lncRNA, and viral RNAs, Stellaris-based methods have been extended to directly and quantitatively detect chromosomal diseases caused by translocations and aberrant splice junctions and single-nucleotide polymorphisms.
Meridian Bioscience’s Illumigene group A Streptococcus and group B Streptococcus tests have been recategorized under CLIA as moderate complexity. The new categorization of these tests allows the Illumigene platform to be available to all moderate-complexity labs in U.S. hospitals and clinics, allowing them to offer an accurate, rapid, simple molecular test for each of these pathogens.
Audit MicroControls’ MicroFD urine chemistry control, two levels, is intended to simulate human patient samples for monitoring the precision of laboratory testing procedures for urine chemistry assays, including amylase, calcium, chloride, creatinine, glucose, magnesium, microalbumin, microprotein, phosphorous, potassium, sodium, urea nitrogen, and uric acid.
Quest Diagnostics offers a clinical test panel for aiding the diagnosis of suspected dementia due to treatable forms of cognitive impairment. The panel is believed to be the first commercial service from a clinical laboratory to combine several guideline-recommended tests for identifying secondary, treatable causes of dementia as a single blood test and report.
